title: Methods to evaluate cytotoxicity and immunosuppression of combustible tobacco product preparations.
abstract: Among other pathophysiological changes, chronic exposure to cigarette smoke causes inflammation and immune suppression, which have been linked to increased susceptibility of smokers to microbial infections and tumor incidence. Ex vivo suppression of receptor-mediated immune responses in human peripheral blood mononuclear cells (PBMCs) treated with smoke constituents is an attractive approach to study mechanisms and evaluate the likely long-term effects of exposure to tobacco products. Here, we optimized methods to perform ex vivo assays using PBMCs stimulated by bacterial lipopolysaccharide, a Toll-like receptor-4 ligand. The effects of whole smoke-conditioned medium (WS-CM), a combustible tobacco product preparation (TPP), and nicotine were investigated on cytokine secretion and target cell killing by PBMCs in the ex vivo assays. We show that secreted cytokines IFN-γ, TNF, IL-10, IL-6, and IL-8 and intracellular cytokines IFN-γ, TNF-α, and MIP-1α were suppressed in WS-CM-exposed PBMCs. The cytolytic function of effector PBMCs, as determined by a K562 target cell killing assay was also reduced by exposure to WS-CM; nicotine was minimally effective in these assays. In summary, we present a set of improved assays to evaluate the effects of TPPs in ex vivo assays, and these methods could be readily adapted for testing other products of interest.
authors: Department of Microbiology and Immunology, Wake Forest University Health Sciences; sarimill@wakehealth.edu.
authors: Subhashini
authors: S
authors: Arimilli
authors: Department of Microbiology and Immunology, Wake Forest University Health Sciences.
authors: Brad E
authors: BE
authors: Damratoski
authors: R&D Department, R.J. Reynolds Tobacco Company.
authors: Prasad
authors: P
authors: G L
mesh_terms: D000328:Adult; D002460:Cell Line; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D009538:Nicotine / Q000494:pharmacology; D052638:Particulate Matter / Q000737:chemistry / Q000633:toxicity; D011650:Pulmonary Alveoli / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D012906:Smoke / Q000009:adverse effects* / Q000032:analysis; D062789:Tobacco Products
chemical_list: D016207:Cytokines; D052638:Particulate Matter; D012906:Smoke; D009538:Nicotine
references: Cryo Letters. 2012 Sep-Oct;33(5):376-84
references: 23224370
references: Tob Control. 2009 Aug;18(4):324-32
references: 19240228
references: Biochem Biophys Res Commun. 1998 Nov 9;252(1):249-56
references: 9813178
references: Toxicol In Vitro. 2013 Feb;27(1):282-91
references: 22960471
references: Cytometry. 1992;13(2):204-8
references: 1547670
references: Respir Res. 2005 Jul 19;6:74
references: 16029496
references: Am J Respir Cell Mol Biol. 2004 Apr;30(4):500-9
references: 15033639
references: Nicotine Tob Res. 2014 Aug;16(8):1045-9
references: 24638850
references: J Cell Physiol. 2008 Jan;214(1):27-37
references: 17541958
references: FASEB J. 2004 Dec;18(15):1897-9
references: 15456740
references: Blood. 1996 Mar 15;87(6):2411-8
references: 8630405
references: Regul Toxicol Pharmacol. 2012 Dec;64(3):350-60
references: 22996032
references: J Immunol Methods. 2007 Aug 31;325(1-2):51-66
references: 17617419
references: Nat Rev Immunol. 2002 May;2(5):372-7
references: 12033743
references: Nicotine Tob Res. 2012 Jan;14(1):7-17
references: 21460383
references: J Immunol. 2004 Sep 15;173(6):4164-70
references: 15356167
references: Toxicol In Vitro. 2013 Sep;27(6):1992-2004
references: 23851003